A novel IO target with a chequered history is starting to look more promising - which one and why?
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?
A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed
A critical look at the early stage BMS oncology pipeline
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
It's time to turn our attention to novel TKI approaches in hematologic malignancies
What caught our attention on novel bispecific antibodies at ASH20?
Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy
Commentary on Saturday at ASH20
W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on
New developments in the BTK niche offer fresh insights on progress
Rock around the CAR-T cell clock to learn what to watch out for at ASH20!
What's hot on the antibody and ADC front at ASH 2020?
Updated look at the bispecific landscape in early clinical development